Sign in

You're signed outSign in or to get full access.

Gwenael Rouy-Poirier

Director at Coda Octopus Group
Board

About Gwenaël Rouy-Poirier

Gwenaël Rouy-Poirier (age 51) is an independent director of CODA, elected in April 2024; he brings 27+ years of finance leadership across aerospace, defense, and medtech and holds a Master of Management in Corporate Finance from EDHEC and a Bachelor in Mathematics from Lycée Victor Duruy . He has served as CFO at GKN Aerospace, Nobel Biocare Systems, and SHL Medical, and currently advises companies as an independent consultant; he joined CODA’s board following expansion to seven seats and received a time-based equity inducement grant that vested on the first anniversary of his election . His tenure at CODA spans April 2024–present; the Board deems him independent under NASDAQ rules .

Past Roles

OrganizationRoleTenureCommittees/Impact
GKN AerospaceChief Financial OfficerApr 2021 – Dec 2022Led profitability roadmap and efficiency initiatives
SHL Medical (Scandinavian Health Ltd.)Interim Chief Financial OfficerMay 2023 – Dec 2023Private, PE-backed medtech; device manufacturing; interim stabilization role
Nobel Biocare SystemsChief Financial Officer2019 – 2021Premium dental implant/digital technologies; finance leadership
Honeywell (Aerospace, HBT, Specialty Materials)Finance leadership rolesPrior years (various)Multi-division finance experience in aerospace and industrials
L’OréalFinance rolePrior yearsConsumer sector finance experience
Arthur AndersenEarly careerPrior yearsAudit/finance foundation

External Roles

OrganizationRoleTenureNotes
Independent consultant (Aerospace & Defense)ConsultantJan 2024 – presentSwitzerland-based; advises sector companies
Other public company directorshipsNone disclosed in CODA filings

Board Governance

  • Independence: Independent under NASDAQ standards; CODA’s only non-independent directors are the CEO (Annmarie Gayle) and Dr. McFadzean .
  • Committees (FY 2024/2025 service):
    • Audit Committee member; Audit met 4x in FY 2024; chair is Michael Hamilton; all members deemed independent and Hamilton designated “financial expert” .
    • Compensation Committee member; Compensation met 4x in FY 2024; chair is Michael Hamilton; all members independent .
    • Nominating & Governance Committee member; Nominating met 3x in FY 2024; all members independent .
  • Attendance: Board met 4x in FY 2024 with 4 unanimous written consents; all directors attended all Board and their committee meetings .
  • Board leadership: Combined Chair/CEO; no designated Lead Independent Director; board monitors structure .

Fixed Compensation

PeriodCash Retainer/Fees ($)Meeting Fees ($)Committee Fees ($)Total Cash ($)
FY 202427,083 27,083

Notes: CODA reports “Fees Earned or Paid in Cash” for directors; no separate meeting or committee fees are disclosed for Rouy-Poirier in FY 2024 .

Performance Compensation

PeriodAward TypeGrant DateShares / UnitsFair Value ($)Vesting SchedulePerformance Metrics
Apr 2024 (inducement)Common stock (time-based)Apr 10–15, 20247,898 shares 100% on Apr 15, 2025 None (time-based)
FY 2024Stock Awards (Director)50,000 Not specifiedNot specified

Notes: The inducement grant is separate from annual director stock awards and vests one year after election; CODA does not disclose a fair value for the inducement in the 8-K, and the FY 2024 director stock award for Rouy-Poirier is reported as $50,000 without detailed grant-date terms in the proxy .

Other Directorships & Interlocks

CompanyRoleCommittee RolesPotential Interlocks
None disclosedNone disclosed in CODA filings

Expertise & Qualifications

  • Finance leadership across aerospace, defense, and medtech; former CFO at GKN Aerospace (Tier-1 supplier), Nobel Biocare Systems, and SHL Medical .
  • Education: Master of Management in Corporate Finance (EDHEC), Bachelor in Mathematics (Lycée Victor Duruy) .
  • Global operating exposure across Europe, Asia, US, and UK; ties to defense industry .

Equity Ownership

Snapshot DateTotal Beneficial Ownership (shares)Ownership %Vested vs UnvestedPledged/Hedged
Aug 12, 2024 (record date July 30, 2024)0 (does not include 7,898 unvested) <1% Unvested: 7,898 vesting 4/15/2025 None disclosed
Aug 1, 2025 (record date July 30, 2025)7,898 <1% Vested: 7,898; Unvested: 0 None disclosed

Governance Assessment

  • Strengths: Full attendance; multi-committee engagement (Audit, Compensation, Nominating), independence, and relevant finance/defense expertise; Audit oversight supported by designated “financial expert” chair .
  • Alignment: Holds 7,898 shares post-vesting; received $50,000 in equity awards in FY 2024; the inducement grant was time-based, promoting retention alignment rather than discretionary cash .
  • Shareholder signals: 2025 AGM results show strong support for directors and say-on-pay (e.g., Rouy-Poirier received 6,816,731 votes for with 277,062 withheld; say‑on‑pay garnered 7,016,633 for vs. 30,857 against) .
  • Conflicts/related-party: Company reports no related-party transactions requiring disclosure; Section 16 compliance monitored with no late filings noted for FY 2024 .
  • RED FLAGS: Structural governance—combined Chair/CEO with no Lead Independent Director; compensation details lack performance conditions for director equity (time-based vesting only) .

Additional context: Auditor ratification passed with broad support; CODA maintains a clawback policy aligned with Nasdaq Rule 5608 (primarily for covered executives) .

Board Governance (Detail)

CommitteeRoleChairMeetings (FY 2024)Independence
AuditMemberMichael Hamilton4 All members independent; Hamilton is “financial expert”
CompensationMemberMichael Hamilton4 All members independent
Nominating & GovernanceMember3 All members independent

Fixed Compensation (Director-Level)

FYFees Earned or Paid in Cash ($)
202427,083

Performance Compensation (Director-Level)

FYStock Awards ($)Notes
202450,000 Annual director equity; separate inducement grant of 7,898 shares with 1-year vest

Say-on-Pay & Shareholder Feedback (AGM 2025)

ProposalForAgainstAbstain
Approval of NEO Compensation (Advisory)7,016,633 30,857 43,303

Director Election Results (AGM 2025)

NomineeForWithheld
Gwenaël Rouy-Poirier6,816,731 277,062

Related-Party & Conflicts

  • CODA reports “None that are required to be reported herein” for related person transactions in both 2024 and 2025 proxies; no loans or family relationships disclosed .
  • Stock pledging/hedging: No disclosures of pledging for Rouy-Poirier; beneficial ownership tables and related-party sections do not indicate pledges .

Compensation Structure Analysis

  • Mix: FY 2024 compensation consists of cash fees ($27,083) and equity ($50,000), indicating a meaningful equity component for alignment; no meeting or chair fees disclosed for him .
  • Performance linkage: Director awards are time-based (inducement vest on first anniversary); CODA does not disclose performance metrics for director equity .
  • Clawback: Policy adopted Sept 7, 2023, applies to covered executives under Nasdaq Rule 5608 and Exchange Act Rule 10D‑1; no director-specific clawback terms disclosed .

Expertise & Qualifications (Detail)

  • Education: EDHEC (Master of Management in Corporate Finance); Lycée Victor Duruy (Bachelor in Mathematics) .
  • Sector specialization: Aerospace/Defense finance leadership; Honeywell, GKN Aerospace; breadth across industrials and medtech .
  • Geographic breadth: Experience across Asia, USA, UK, Europe; based in Switzerland .

Equity Ownership (Detail)

HolderSharesPercent of Common Stock
Gwenaël Rouy-Poirier (Aug 1, 2025)7,898 <1%
Gwenaël Rouy-Poirier (Aug 12, 2024)0 (note: 7,898 to vest 4/15/2025) <1%

Governance Summary for Investors

  • Board effectiveness: Rouy-Poirier enhances financial oversight as a multi-committee independent director with full attendance; Audit Committee anchored by a designated financial expert chair .
  • Confidence signals: Strong shareholder support in 2025 election and say-on-pay; balanced director pay with equity component; no related-party exposures disclosed .
  • Watch items: Absence of Lead Independent Director with combined CEO/Chair role; director equity appears time-based without disclosed performance metrics—monitor for any evolution toward performance-conditioned director awards .